Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Full or fractional third-dose COVID-19 booster vaccination after two-dose CoronaVac
ISRCTN47074508Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 4, randomised, double-blind trial of tozinameran, ChAdOx1 nCoV-19 and coronavac in coronavirus disease 2019 (COVID-19), sponsored by University of Oxford. Started Mar 2022; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN47074508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47074508.